ST BERNARDS MEDICAL CENTER
- Type
- Teaching hospital
- Where
- Jonesboro, AR
- Medicare CCN
- 040020
- Received
- $484,058 in 55 records, 2020 ($333 general, $483,724 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: ST BERNARDS MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 4 | $333 |
| 2020 | Research payment | 51 | $483,724 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 2 | $286,888 | 2020 |
| Boston Scientific Corporation | 14 | $59,362 | 2020 |
| Eli Lilly and Company | 4 | $40,953 | 2020 |
| E.R. Squibb & Sons, L.L.C. | 1 | $23,062 | 2020 |
| Baxter Healthcare | 2 | $20,507 | 2020 |
| Amgen Inc. | 9 | $15,562 | 2020 |
| Incyte Corporation | 3 | $12,578 | 2020 |
| PFIZER INC. | 1 | $8,500 | 2020 |
| Celgene Corporation | 1 | $5,735 | 2020 |
| CSL Behring | 2 | $4,195 | 2020 |
| SEAGEN INC. | 1 | $4,000 | 2020 |
| Pharmacyclics LLC, an AbbVie Company | 9 | $1,350 | 2020 |
| Merck Sharp & Dohme LLC | 2 | $1,027 | 2020 |
| LEICA MICROSYSTEMS INC. | 3 | $296 | 2020 |
| GE HEALTHCARE | 1 | $37 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 51 | $483,724 |
| Gift | 3 | $296 |
| Grant | 1 | $37 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-21 | Boston Scientific Corporation | $6,134 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | DES BTK | 2020 |
| 2020-11-16 | Boston Scientific Corporation | $7,686 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | DES BTK | 2020 |
| 2020-11-11 | Boston Scientific Corporation | $309 | Research payment | In-kind items and services | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | DES BTK | 2020 |
| 2020-11-11 | Boston Scientific Corporation | $2 | Research payment | In-kind items and services | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | DES BTK | 2020 |
| 2020-10-19 | Boston Scientific Corporation | $9,323 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | DES BTK | 2020 |
| 2020-10-09 | Amgen Inc. | $1,078 | Research payment | In-kind items and services | Nplate Biological, Hematology | LCM:A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 1 | 2020 |
| 2020-09-30 | Incyte Corporation | $4,446 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-09-30 | Incyte Corporation | $3,578 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-09-29 | Baxter Healthcare | $9,301 | Research payment | Cash or cash equivalent | Renal - Amia Device, Renal | Performance evaluation of the AMIA Automated Peritoneal Dialysis -APD- Solution Generation System in patients using the | 2020 |
| 2020-09-25 | SEAGEN INC. | $4,000 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas | 2020 |
| 2020-09-14 | Novartis Pharmaceuticals Corporation | $284,120 | Research payment | Cash or cash equivalent | KISQALI Drug, ONCOLOGY | RIBOCICLIB STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR HER2 EARLY BC AT HIGH AMP INTERMEDIATE RISK FOR RECURRENCE | 2020 |
| 2020-08-29 | PFIZER INC. | $8,500 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA | 2020 | |
| 2020-08-21 | Amgen Inc. | $925 | Research payment | In-kind items and services | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC. | 2020 |
| 2020-08-04 | Boston Scientific Corporation | $2,449 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | DES BTK | 2020 |
| 2020-07-28 | Merck Sharp & Dohme LLC | $787 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2020 |
| 2020-07-06 | Boston Scientific Corporation | $9,702 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | DES BTK | 2020 |
| 2020-07-06 | Boston Scientific Corporation | $1,144 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | DES BTK | 2020 |
| 2020-06-23 | CSL Behring | $3,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-06-23 | Amgen Inc. | $2,500 | Research payment | Cash or cash equivalent | Nplate Biological, Hematology | LCM: A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 2 | 2020 |
| 2020-06-15 | Merck Sharp & Dohme LLC | $240 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab | 2020 |
| 2020-06-11 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-06-08 | Boston Scientific Corporation | $6,516 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | DES BTK | 2020 |
| 2020-06-02 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-06-02 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-06-02 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-06-02 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-05-20 | Boston Scientific Corporation | $370 | Research payment | In-kind items and services | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | DES BTK | 2020 |
| 2020-04-20 | Boston Scientific Corporation | $4,452 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | DES BTK | 2020 |
| 2020-04-17 | Amgen Inc. | $2,593 | Research payment | In-kind items and services | Nplate Biological, Hematology | LCM: A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 2 | 2020 |
| 2020-04-08 | Amgen Inc. | $71 | Research payment | In-kind items and services | Nplate Biological, Hematology | LCM:A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 1 | 2020 |
| 2020-03-27 | Amgen Inc. | $925 | Research payment | In-kind items and services | Nplate Biological, Hematology | LCM:A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 1 | 2020 |
| 2020-03-26 | CSL Behring | $1,195 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-03-16 | Boston Scientific Corporation | $4,882 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | DES BTK | 2020 |
| 2020-03-16 | LEICA MICROSYSTEMS INC. | $195 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-03-16 | LEICA MICROSYSTEMS INC. | $77 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-03-16 | LEICA MICROSYSTEMS INC. | $22 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | 2020 | |
| 2020-03-10 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-03-10 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-03-10 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-03-10 | Pharmacyclics LLC, an AbbVie Company | $150 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1134M-CA | 2020 |
| 2020-02-18 | Boston Scientific Corporation | $2,341 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | DES BTK | 2020 |
| 2020-02-17 | Celgene Corporation | $5,735 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology | Celgene - Connect MDS/AML | 2020 |
| 2020-02-13 | Novartis Pharmaceuticals Corporation | $2,768 | Research payment | Cash or cash equivalent | VOTRIENT Drug, ONCOLOGY | A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PAZOPANIB AS ADJUVAN | 2020 |
| 2020-02-10 | Amgen Inc. | $17 | Research payment | In-kind items and services | Nplate Biological, Hematology | LCM:A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 1 | 2020 |
| 2020-02-05 | E.R. Squibb & Sons, L.L.C. | $23,062 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Lung cancer molecular profiling and clinical outcomes in US oncology community practices | 2020 |
| 2020-01-30 | Amgen Inc. | $7,446 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC. | 2020 |
| 2020-01-28 | Eli Lilly and Company | $1,154 | Research payment | In-kind items and services | A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN | 2020 | |
| 2020-01-28 | Eli Lilly and Company | $387 | Research payment | In-kind items and services | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD | 2020 | |
| 2020-01-22 | Incyte Corporation | $4,554 | Research payment | Cash or cash equivalent | Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S | 2020 | |
| 2020-01-21 | Eli Lilly and Company | $22,853 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD | 2020 | |
| 2020-01-21 | Boston Scientific Corporation | $4,047 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | DES BTK | 2020 |
| 2020-01-17 | Eli Lilly and Company | $16,559 | Research payment | Cash or cash equivalent | A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN | 2020 | |
| 2020-01-13 | Baxter Healthcare | $11,205 | Research payment | Cash or cash equivalent | Renal - Amia Device, Renal | Performance evaluation of the AMIA Automated Peritoneal Dialysis -APD- Solution Generation System in patients using the | 2020 |
| 2020-01-09 | Amgen Inc. | $4 | Research payment | In-kind items and services | GALACTIC - HF | 2020 | |
| 2020-01-08 | GE HEALTHCARE | $37 | Grant | In-kind items and services | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Jonesboro, AR, county Craighead County, AR, state Arkansas; placed by its city name.
| Measure | Place (city or town) Jonesboro, AR | County Craighead County, AR | State Arkansas |
|---|---|---|---|
| Population B01003 | 80,137 | 113,249 | 3,049,391 |
| Population, 2020 census P1 | 78,576 | 111,231 | 3,011,524 |
| Median age B01002 | 33.9 | 34.5 | 38.5 |
| Under 18 B01001 | 24.0% | 25.2% | 23.1% |
| 65 and over B01001 | 14.2% | 13.9% | 17.6% |
| Households B11001 | 31,913 | 44,437 | 1,205,987 |
| Foreign born B05002 | 4.6% | 3.7% | 5.4% |
| Median household income B19013 | $55,424 | $59,548 | $60,773 |
| Median family income B19113 | $72,057 | $75,703 | $76,968 |
| Per capita income B19301 | $33,544 | $33,774 | $34,225 |
| Poverty rate B17001 | 22.8% | 20.1% | 16.0% |
| Unemployment rate B23025 | 6.3% | 5.6% | 4.9% |
| Civilian labor force B23025 | 38,912 | 55,535 | 1,411,269 |
| Mean commute (minutes) B08013 | 18.0 | 19.6 | 22.5 |
| Bachelor's degree or higher B15003 | 31.8% | 29.7% | 25.7% |
| Housing units B25001 | 35,002 | 48,885 | 1,394,673 |
| Owner-occupied B25003 | 54.3% | 60.1% | 66.4% |
| Renters B25003 | 45.7% | 39.9% | 33.6% |
| Median home value B25077 | $223,200 | $210,400 | $188,000 |
| Median gross rent B25064 | $956 | $958 | $947 |
| White, not Hispanic B03002 | 63.0% | 70.8% | 67.4% |
| Black B03002 | 22.7% | 16.6% | 14.6% |
| Hispanic or Latino B03002 | 7.5% | 6.3% | 9.0% |
| Asian B03002 | 1.6% | 1.2% | 1.6% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.3% |
Economy now FRED unemployment 3.9% in Sep 2026 (4.2% a year earlier); per capita personal income $61,697 in 2025, up 31% in five years (+5.2% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Jonesboro, AR.
Comments